Skip to content
★ Sign in to follow
Autobio Diagnostics Co., Ltd. logo

Autobio Diagnostics Co., Ltd. Stock: price and insider trades · China

安图生物

CN·Mcap CN¥18.4BHealth Care

No insider purchase over the last 90 days. The latest, by 苗拥军, was filed 04 Jul 2024.

Autobio Diagnostics Co., Ltd.: what insiders have been doing

This page follows insider dealings at Autobio Diagnostics Co., Ltd. as filed with SSE / SZSE (CSRC), a company from the Health Care sector based in People's Republic of China. The group dates from 1999. Autobio Diagnostics Co., Ltd. has had no insider filing for more than a year; the last one goes back to 4 July 2024.

Looking back to 2024, when coverage begins, insiders filed 2 purchases and no sales.

For comparison within the same sector, see the insider buying recorded at Dynavox Group AB and Vetoquinol SA. Every figure here comes from the filings published by SSE / SZSE (CSRC) and describes the past, not future prices; it is not investment advice.

Key facts

Headquarters: People's Republic of China · Founded: 1999

Source: Wikidata (CC0).

Insider Decl.
2
Thresholds
n/a
Buy Volume
€7M
2 ops. · all time
Sell Volume
n/a
n/a

Since the insiders bought

  • Filed 04 Jul 2024 · 857 days ago · €123k
    -13.0%
    Entry CN¥43.56 · Close at T+365 CN¥37.91

Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.

This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.

Fundamental score
Ranked 3,393 of 26,914 companies
72.0
score / 100
Value
59
Quality
85
FCF yld4.0%
Earn yld5.8%
EV/EBITDA10.9x
ROE12%
Gross mgn66%
Net mgn25%
Debt/EBITDA0.0x
Pillars2/3

Transparent value + quality ranking, distinct from the insider signal.

Financial data

as of FY 2025

FY ended December 2025 · cache

CN¥32.22
Analyst consensus
4 analysts
·
CN¥29.50Target CN¥38.19(+19%)CN¥42.00
Income statement
RevenueCN¥4.2B
Gross profitCN¥2.8B66% margin
EBITDACN¥1.7B40% margin
Net incomeCN¥1.1B23.5% margin
Valuation
PER (trailing)18.3x
P/Book2.1x
Beta0.00
Balance sheet & cash
Market capCN¥18.4B
Total debtCN¥59.1M
Free Cash FlowCN¥737.4M
Debt / Equity1%
Profitability & ownership
ROE11.7%
ROA5.5%
% insiders71.3%
% institutions7.1%
Last declaration on 4 July 2024
Declarations2 total
  • ▲
    董事Executives
    964,634 CNY7SSE
    22,000 shares1.8% of flowA股XSHGSSE:173000007818830820
    Canonical exit: 2 Oct 2024 (T+90)
  • ▲
    董事Executives
    50M CNY15SSE
    901,200 shares98.2% of flowA股XSHGSSE:173000007534840580
    Canonical exit: 22 Jul 2024 (T+90)

2 of 2 declarations

About Autobio Diagnostics Co., Ltd.

安图生物 is a company focused on the health and pharmaceutical sector, providing diagnostic solutions and biopharmaceutical products. It is listed on the XSHG market.

Recent ranked signals in the same sector

Purchases our model currently ranks for the recommendations list.

All recommendations